• Legislative and regulatory frameworks
• Limited circumstances under which imports/exports are authorized
• Import/Export Permits issuance process

Present by:

Alice Gheorghiu, Manager of Hemp and Import/Export
Controlled Substances and Cannabis Branch, Health Canada
Direction générale des substances contrôlées et du cannabis, Santé Canada

• Legal status of medical marijuana under international law
• Legal status of medical marijuana import/export under international law
• Import permits and requirements
• International Narcotics Control Board reporting requirements
• Export to the United States

Present by: Vincent Sliwoski, partner, Harris Bricken

• Law frameworks ( Argentina, Brazil, Chile, Colombia, Uruguay)
• Permits and requirements
• Public bodies involved
• Maintaining a Quality System – the challenges that businesses face
• Import/Export for compassionate use

Present by: Daniel Podestá, partner, Estudio Podestá

• Business cases that require GMP
• How long does it take
• Where does GMP start
• Importation into the EU

Present by:

Karina Lahnakoski, Partner, Risk Advisory, CCI Deloitte, Deloitte LLP

Valentina Vaguengueim, Senior Manager, Risk Advisory, CCI Deloitte, Deloitte LLP

Present by:

Marion Zammit, Malta’s Government economic development agency, responsible for supporting the Medical Cannabis Industry, along with other sectors

• Legalisation of Cannabis in South Africa: High on our list of priorities
• Regulatory and Compliance requirements
• Medicinal Cannabis in South Africa: Regulatory requirements for import/export
• Licences, and permit requirements

Present by: Martha Smit, Partner, Qualified registered nurse and lawyer, Fasken, Johannesburg

To be Confirmed

Present by:

Céline Beaupré, Manager of Specialized Authorization
Controlled Substances and Cannabis Branch, Health Canada
Direction générale des substances contrôlées et du cannabis, Santé Canada

• Legalisation of Cannabis in South Africa: High on our list of priorities
• The framework for Research and Clinical Trials: The South African context
• The current status of clinical data trials for an international Medical Cannabis

Present by: Martha Smit, Partner, Qualified registered nurse and lawyer, Fasken, Johannesburg

Updated review of the CARE-E study

Dr. Richard J. Huntsman, MD, FRCP(C), CSCN(EEG),
Jim Pattison Children’s Hospital Foundation, University of Saskatchewan

• Phytochemistry of cannabis
• Trends in developing cannabis plant genetics
• Trends in the biosynthesis of cannabinoids
• Trends in the biosynthesis of non-cannabinoid phytochemicals

Present by:

Dr. Yang Qu, assistant professor and Cannabis Health Research Chair at University of New Brunswick

• Cannabis use is growing in the senior population – is the Canadian healthcare system keeping pace ?
• Cannabis use vs pharmaceutical use : patient experiences and risks
• Challenges with cannabis research : practical and theoretical

Present by:

Dr. Jamie R. Cox, MD

A growing number of pediatricians in Canada report that children and young adults are using cannabis for a variety of medical purposes including cancer symptoms, pain, sleep and neurological conditions among others. This talk will cover

• Perspectives on cannabis use for child health concerns
• The need for clinical trials
• Steps forward to evidence-based medical cannabis use in children

Present by:

Lauren E Kelly Ph.D., M.Sc., C.C.R.P., University of Manitoba, Canadian Childhood Cannabinoid Clinical Trails, Centre for Healthcare Innovation

With the restrictions on cannabinoid research finally easing off we are learning more and more about the therapeutic properties of cannabis beyond THC and CBD. New data shines the light at the vast potential minor cannabinoids may carry.

• Existing data on efficacy of minor cannabinoids
• Pharma and biotech interest in minor cannabinoid drug development
• Cannabinoid biosynthesis feasible for production of minor cannabinoids
• Discovery and characterization of novel cannabinoid molecules

Present by:

Dr. Olga Chernoloz, Specialist in Neuropsychopharmacology, Head of Omnica Biotech

REMS is a drug safety program the United States Food and Drug Administration (FDA) can require for certain medications, which have been determined to have safety concerns to ensure the benefits of the therapy outweigh its risks.

Traditional views regarding REMS programs primarily concerned highly addictive drugs, such as opiates. However, with the increasing number of cannabis therapies, i.e., medical marijuana prescriptions for therapeutic applications, there is a need to consider dependence on cannabis in all of its forms for medicinal use.

This presentation discusses:

• Emerging REMS-type programs for cannabis therapies
• Development of a shared system for REMS for cannabis therapies
• The decisions that need to be made in order to promote positive REMS enforcement to patients

Present by:

Dr. Willis H. Thomas, PhD, PMP, CPT, PQE Group

Details available soon

Present by:

Dr. Lucas C. McCann, MSc., BSc., Co-founder and Chief Scientific Officer, CannDelta Inc.

• Cannabis and Brain Development
• Cannabinoid replacement therapies for professional athletes

Stay Tuned Additional Topics To Be Announced!

Please send me full agenda details